Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyomnaitham, Suvimol, Quan Toh, Zheng, Wongprompitak, Patimaporn, Jansarikit, Laddawan, Srisutthisamphan, Kanjana, Sapsutthipas, Sompong, Jantraphakorn, Yuparat, Mingngamsup, Natthakarn, Licciardi, Paul V, Chokephaibulkit, Kulkanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746495/
https://www.ncbi.nlm.nih.gov/pubmed/35816053
http://dx.doi.org/10.1080/21645515.2022.2091865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746495/
https://www.ncbi.nlm.nih.gov/pubmed/35816053
http://dx.doi.org/10.1080/21645515.2022.2091865

Ejemplares similares